Trial Profile
A randomized, open-label study evaluating the antiviral activity and safety of 3 month Fuzeon induction with an optimized background antiretroviral regimen versus OB alone, in Fuzeon-naive HIV-1 infected patients with virological failure
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Enfuvirtide (Primary) ; Antiretrovirals
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms INNOVE
- Sponsors Roche
- 01 Nov 2012 Primary endpoint 'Virological-response-rate' has not been met.
- 19 Sep 2011 Actual end date (Jun 2011) added as reported by ClinicalTrials.gov.
- 19 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.